Portal de Periódicos da CAPES

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

2015; Springer Nature; Volume: 29; Issue: 5 Linguagem: Inglês

10.1038/leu.2015.29

1476-5551

Nicholas C.P. Cross, Helen White, Dolors Colomer, Hans Ehrencrona, Letizia Foroni, Enrico Gottardi, Thoralf Lange, Thomas Lion, Kateřina Machová Poláková, Stéphanie Dulucq, Giovanni Martinelli, Elisabeth Oppliger Leibundgut, Niels Pallisgaard, Gisela Barbany, Tomasz Sacha, Rodica Tălmaci, Barbara Izzo, Giuseppe Saglio, Fabrizio Pane, Martin C. Müller, Andreas Hochhaus,

Lymphoma Diagnosis and Treatment

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.